Press Release Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 3 hours ago
Press Release Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer Jul 22